Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move
Publishing timestamp: 2024-03-08 11:22:29
Summary
The FDA has delayed its decision on Eli Lilly's experimental Alzheimer's treatment donanemab, pushing back the approval deadline. The drug showed positive results in a late-stage trial but has safety concerns. This delay is a setback for Eli Lilly in the race to compete with other companies in the Alzheimer's treatment market.
Sentiment: MIXED
Tickers: BIIB, LLY, 4523.T-JP,
Keywords: eisai co ltd, pharmaceuticals, biotechnology, health care industry, business news, business, biotech and pharmaceuticals, science, biogen inc, eli lilly and co,
Source: https://www.cnbc.com/2024/03/08/eli-lilly-alzheimers-drug-fda-approval-delayed.html